Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses of the relationship of CD44+/CD24-/low tumor cells to disease-free survival

From: CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
CD44+/CD24-/low tumor cells
High 2.144 1.321-3.479 0.002 1.963 1.163-3.313 0.012
Low 1.000    1.000   
ER status
Positive 0.826 0.524-1.304 0.412 1.425 0.731-2.776 0.298
Negative 1.000    1.000   
PR status
Positive 0.500 0.312–0.800 0.004 0.192 0.088–0.420 0.001
Negative 1.000    1.000   
Her2 status
Positive 0.966 0.614–1.521 0.882 0.692 0.317–1.513 0.357
Negative 1.000    1.000   
Basal-like feature*
Present 2.731 0.461-1.393 0.007 3.902 1.402-10.859 0.009
Absent 1.000    1.000   
TNM stage
Stage III/IV 1.989 0.814–2.626 0.029 1.820 1.051–3.151 0.033
Stage I/II 1.000    1.000   
Lymph node involvement
Absent 0.724 0.427-1.227 0.230 1.081 0.540-2.164 0.827
Present 1.000    1.000   
Age (years)
≥ 50 1.047 0.681–1.610 0.883 1.062 0.627–1.799 0.822
< 50 1.000    1.000   
  1. Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
  2. * Immunohistochemically negative for both SR and Her2.